Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6
Authors' conclusion
Semaglutide treatment improved cardiorenal outcomes versus placebo in people with T2D, regardless of prior CVD and baseline BMI. This improvement was observed even when accounting for changes in BW, indicating direct effects of semaglutide on the cardiorenal system. This analysis supports the broad efficacy of semaglutide in a diverse T2D population.
Study context
- Population
- People with T2D at high cardiovascular (CV) risk, stratified by prior CV disease (CVD) status and baseline body mass index (BMI)
- Comparison
- Semaglutide vs placebo
- Primary endpoint
- Time to primary MACE (CV death, non-fatal MI or non-fatal stroke) by prior CVD and baseline BMI subgroups
Methodological detailssubgroup analysis by prior CVD and baseline BMI
- Subgroup analysis by prior CVD and baseline BMI
Primary result
As reported in the abstract
Primary and expanded MACE, CV death, all-cause death across prior CVD and BMI subgroups
- Semaglutide significantly reduced risk of primary and expanded major adverse CV events (MACE) vs placebo in the overall population
- Nonsignificant risk reduction of CV and all-cause death vs placebo in the overall population
- Effect consistent across all subgroups
- Semaglutide vs Placebo: pINT >0.05 for all comparisons
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| New or worsening nephropathy (SUSTAIN 6 population)Semaglutidevs Placebo | 0.64 (0.46–0.88) | P = 0.0054 | |
| 0.512Hazard ratio (log scale) |
| Outcome | P value |
|---|---|
| New or worsening nephropathy (SUSTAIN 6 population)Semaglutide vs Placebo · consistent across all subgroups | pINT >0.05 for all comparisons |
Primary MACE accounting for body weight (BW) changes (overall and by BMI subgroups)
- Treatment effects remained similar to the main analysis
Original publication
Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6. Diabetes Obes Metab. Published 24 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →